Enterprise Network Standardization
Multi-Site Biologic Infusion Networks
High-volume J-code procurement across multi-specialty portfolios.
Standardizes prior authorization operations across multi-site networks, neutralizing regional payer variability, portal fragmentation, and administrative attrition.
Oncology & Hematology
FOCUS REGIMENS
Opdivo, Keytruda, Yervoy, CheckMate protocols, oral targeted agents.
Parses complex biomarker requirements (PD-L1, EGFR, BRAF, KRAS), tumor staging, and platinum-failure documentation to eliminate high-dollar buy-and-bill denials.
Dermatology & Biologic Therapeutics
Dupixent, Cosentyx, Taltz, Tremfya, Stelara, Skyrizi, Ilumya, Bimzelx. Validates Body Surface Area (BSA) calculations, PASI/IGA severity scores, topical corticosteroid failure timelines, and baseline phototherapy trial proofs.
Rheumatology & Autoimmune Infusion
Stelara, Skyrizi, Simponi ARIA, Orencia, Inflectra, Remicade, Benlysta. Audits synthetic DMARD failure timelines, DAS28/CDAI disease activity scores, and baseline lab screening.
Neurology & Neuromuscular
FOCUS REGIMENS
Ocrevus, Vyvgart, Botox for Chronic Migraine, and CGRP inhibitors including Emgality, Aimovig, and Ajovy. Validates monthly headache frequency logs, quantitative immunoglobulin levels, and prior therapeutic failure proofs.
Our clinical team continuously configures custom drug regimen modules aligned with commercial payer updates.
Request Specialty Audit